General News | Global HIV Vaccine Enterprise

News related to the Enterprise, its Stakeholders, and HIV Vaccine Research

AVAC Calls for Speedy Funding of Critical Microbicide Follow-Up Studies - September 3, 2010

AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only $58 million has been committed. See below for full announcement.

1 attachment

UNAIDS Statement - Road-map agreed for confirmatory trials of promising microbicide - September 3, 2010

Enterprise-OCTAVE workshop on GPP guidelines wrap-up summary - August 30, 2010

The OCTAVE Project (Online Collaborative Training for AIDS Vaccine Evaluation) and the Global HIV Vaccine Enterprise, in collaboration with AVAC: Global Advocacy for HIV Prevention and UNAIDS, conducted a one-day blended learning workshop in Vienna, Austria, prior to the 2010 International AIDS Society Conference.

1 attachment

Gates Foundation Launches RFP to Diversify Pipeline of Product Concepts for an HIV Vaccine within CAVD - August 25, 2010

The Bill & Melinda Gates Foundation is launching a Request for Proposals (RFP) to address four topic areas in order to diversify the pipeline of product concepts for an HIV vaccine within the Collaboration for AIDS Vaccine Discovery (CAVD) initiative.

Doctors to develop anti-HIV gel for SA - August 17, 2010

Speaking at a media briefing in Cape Town, Dr. Zeda Rosenberg, CEO of the International Partnership for Microbicides, described results of the CAPRISA microbicide trial as a “huge achievement,” but emphasized that the candidate gel needs to be tested again to confirm initial findings.

HIV is a 20th-century disease that needs 21st-century research - August 10, 2010

Alan Bernstein and Peter Piot
The Globe and Mail (Canada)
Tuesday, August 10 2010

http://www.theglobeandmail.com/news/opinions/hiv-is-a-20th-century-disease-that-needs-21st-century-research/article1667175/

We need smarter approaches to clinical trials that test more concepts in less time, for less money, while preserving safety, community engagement and ethical guidelines.

NY Times: Advance on AIDS Raises Questions as Well as Joy - July 27, 2010

The New York Times reported on the CAPRISA 004 results in an article today, “Advance on AIDS Raises Questions as Well as Joy.” The story notes that “after more than a dozen microbicide failures, [the results were] a huge relief, and led to cheering and standing ovations for the researchers.” The story can be found at: http://www.nytimes.com/2010/07/27/health/27aids.html.

Advances on HIV Prevention Tools Heralded At Conference - July 23, 2010

The International AIDS Vaccine Initiative (IAVI) issued a statement on advances on HIV prevention tools at the International AIDS Conference in Vienna. The full statement is below.

1 attachment

Update on the Renewed Canadian HIV Vaccine Initiative - July 21, 2010

The Honourable Leona Aglukkaq, Minister of Health in collaboration with the Bill & Melinda Gates Foundation, announced the renewed Canadian HIV Vaccine Initiative (CHVI), which features the creation of the CHVI Research and Development Alliance. The full announcement is available here: http://www.chvi-icvv.gc.ca/index-eng.html.

Statement of Anthony S. Fauci, M.D., on Results from the CAPRISA 004 Microbicide Study - July 20, 2010

The National Institute of Allergy and Infectious Diseases National Institutes of Health congratulate the Centre for the AIDS Program